title: Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity.
abstract: The hemolytic uremic syndrome (HUS) is characterized by hemolytic anemia, thrombocytopenia and renal dysfunction. The typical form of HUS is generally associated with infections by Gram-negative Shiga toxin (Stx)-producing Escherichia coli (STEC). Endothelial dysfunction induced by Stx is central, but bacterial lipopolysaccharide (LPS) and neutrophils (PMN) contribute to the pathophysiology. Although renal failure is characteristic of this syndrome, neurological complications occur in severe cases and is usually associated with death. Impaired blood-brain barrier (BBB) is associated with damage to cerebral endothelial cells (ECs) that comprise the BBB. Astrocytes (ASTs) are inflammatory cells in the brain and determine the BBB function. ASTs are in close proximity to ECs, hence the study of the effects of Stx1 and LPS on ASTs, and the influence of their response on ECs is essential. We have previously demonstrated that Stx1 and LPS induced activation of rat ASTs and the release of inflammatory factors such as TNF-α, nitric oxide and chemokines. Here, we demonstrate that rat ASTs-derived factors alter permeability of ECs with brain properties (HUVECd); suggesting that functional properties of BBB could also be affected. Additionally, these factors activate HUVECd and render them into a proagregant state promoting PMN and platelets adhesion. Moreover, these effects were dependent on ASTs secreted-TNF-α. Stx1 and LPS-induced ASTs response could influence brain ECs integrity and BBB function once Stx and factors associated to the STEC infection reach the brain parenchyma and therefore contribute to the development of the neuropathology observed in HUS.
authors.affiliation: Departamento de Inmunología, CONICET, Ciudad Autónoma de Buenos Aires, Argentina. vilandoni@yahoo.com.ar
authors.forename: Verónica I
authors.initials: VI
authors.lastname: Landoni
authors.forename: Pablo
authors.initials: P
authors.lastname: Schierloh
authors.forename: Marcelo
authors.initials: M
authors.lastname: de Campos Nebel
authors.forename: Gabriela C
authors.initials: GC
authors.lastname: Fernández
authors.forename: Cecilia
authors.initials: C
authors.lastname: Calatayud
authors.forename: María J
authors.initials: MJ
authors.lastname: Lapponi
authors.forename: Martín A
authors.initials: MA
authors.lastname: Isturiz
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism; D001812:Blood-Brain Barrier; D001921:Brain / Q000098:blood supply; D002463:Cell Membrane Permeability / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D017077:Culture Media, Conditioned / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000473:pathology; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology*; D051381:Rats; D022622:Shiga Toxin 1 / Q000633:toxicity*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D017077:Culture Media, Conditioned; D008070:Lipopolysaccharides; D022622:Shiga Toxin 1; D014409:Tumor Necrosis Factor-alpha